Loading insider details...
Beta
Latest Form 4 (Sep 28, 2026): Grant/Award of 20,986 LEGN shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 28, 2026 | Legend Biotech Corp (LEGN) | Grant/Award | 20,986 | n/a |
| May 29, 2026 | EXELIXIS, INC. (EXEL) | Grant/Award | 8,367 | n/a |
| Dec 9, 2025 | Akero Therapeutics, Inc. (AKRO) | Disposition to Issuer | 9,398 | n/a |
| Jun 5, 2025 | Akero Therapeutics, Inc. (AKRO) | Grant/Award | 9,398 | n/a |
| May 30, 2025 | EXELIXIS, INC. (EXEL) | Grant/Award | 9,812 | n/a |
| May 22, 2025 | EXELIXIS, INC. (EXEL) | Sale | 4,544 | $201.3K |
| Jun 11, 2024 | Akero Therapeutics, Inc. (AKRO) | Grant/Award | 26,000 | n/a |
| Jun 7, 2024 | OptiNose, Inc. (OPTN) | Grant/Award | 75,000 | n/a |
| Jun 5, 2024 | EXELIXIS, INC. (EXEL) | Grant/Award | 18,838 | n/a |
| Jun 27, 2023 | Akero Therapeutics, Inc. (AKRO) | Grant/Award | 15,000 | n/a |